Buy­out buzz hits fever pitch on re­port that Nek­tar is ‘ex­plor­ing op­tions’

The buzz about a pos­si­ble ac­qui­si­tion of Nek­tar Ther­a­peu­tics $NK­TR has been in­tense over the last few weeks, es­pe­cial­ly as new M&A deals have be­gun …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.